Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | pantothenate kinase, putative | 0.0077 | 1 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0077 | 1 | 1 |
Plasmodium vivax | pantothenate kinase, putative | 0.0077 | 1 | 0.5 |
Schistosoma mansoni | pantothenate kinase | 0.0077 | 1 | 0.5 |
Trypanosoma cruzi | pantothenate kinase subunit, putative | 0.0077 | 1 | 0.5 |
Echinococcus granulosus | pantothenate kinase 4 | 0.0077 | 1 | 0.5 |
Plasmodium falciparum | pantothenate kinase 1, putative | 0.0077 | 1 | 0.5 |
Trypanosoma brucei | pantothenate kinase subunit, putative | 0.0077 | 1 | 0.5 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0077 | 1 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0077 | 1 | 1 |
Trichomonas vaginalis | pantothenate kinase, putative | 0.0077 | 1 | 1 |
Giardia lamblia | Pantothenate kinase 4 | 0.0077 | 1 | 0.5 |
Onchocerca volvulus | Fumble homolog | 0.0077 | 1 | 0.5 |
Loa Loa (eye worm) | pantothenate kinase | 0.0077 | 1 | 0.5 |
Trypanosoma cruzi | pantothenate kinase subunit, putative | 0.0077 | 1 | 0.5 |
Echinococcus multilocularis | pantothenate kinase 4 | 0.0077 | 1 | 0.5 |
Leishmania major | pantothenate kinase subunit, putative | 0.0077 | 1 | 0.5 |
Entamoeba histolytica | pantothenate kinase 1, putative | 0.0077 | 1 | 0.5 |
Toxoplasma gondii | fumble protein | 0.0077 | 1 | 0.5 |
Schistosoma mansoni | pantothenate kinase | 0.0077 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 97 % | Inhibition of human recombinant FLT3 expressed in insect cells using Ulight-CAGAGAIETDKEYYTVKD as substrate at 10 uM after 90 mins by LANCE method relative to staurosporine | ChEMBL. | 23107479 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.